Prostate Cancer : Update Bulletin # 2 [April 2019]

This edition presents key opinion leader (KOL) views on recent developments in the prostate cancer market. Topics covered include: Bristol-Myers Squibb announcing positive interim data from the CheckMate 650 assessing Opdivo (nivolumab) and Yervoy (ipilimumab) in metastatic castration-resistant prostate cancer (mCRPC); Janssen presenting preliminary data from the Phase II GALAHAD study assessing niraparib in patients with mCRCP at the American Society of Clinical Oncology Genitourinary Cancers Symposium (14-16 February 2019) In San Francisco, CA, USA; Onoclogy Ventures announcing that the first patient had been dosed in a Phase II study of LiPlaCis, its liposomal formulation of cisplatin.

Business Questions:

• What are the experts' reactions to the data from Opdivo and Yervoy's Phase II trial in mCRPC?
• How do the KOLs envisage Opdivo and Yervoy to be utilised in the treatment of prostate cancer?
• What was the KOLs opinion on the preliminary data from the Phase II GALAHAD trial?
• Where in the treatment paradigm could niraparib be utilised if approved?
• What potential has the liposomal cisplatin product LiPlaCis have in the treatment of prostate cancer?
• What potential patient population could LiPlaCis be used in, and what role will biomarker testing play?